ArticleDiabetology international2019

Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study.

Hisamitsu Ishihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.